Navigation Links
Diabetic retinopathy research could reduce screening costs
Date:5/6/2012

Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually.

The research is supported by funding from the National Institute for Health Research Peninsula Collaboration for Leadership in Applied Health Research and Care (NIHR PenCLAHRC). It is published today (00:01hrs BST Monday 7th May 2012) on-line in Diabetes Care.

Diabetic retinopathy is a common complication of diabetes. It occurs when high blood sugar levels damage the cells in the retina and, if not treated, can lead to blindness. In all but some cases diabetic retinopathy has a typically slow rate of progression and can take years to develop.

The research team developed a model that simulated the progression of retinopathy in type 2 diabetes and related screening, in order to predict the rates of retinopathy-related sight loss. The model used data from the Royal Devon & Exeter NHS Foundation Trust in the South West of the UK and the research team generated comparative 15-year forecasts to assess the differences between current screening policies and those proposed by the findings of the study.

The study concluded that it is safe to screen type 2 diabetes patients who have not been diagnosed with retinopathy every two years rather than annually, because the research team found that the proportion of patients who develop retinopathy-related sight loss was no different between the two screening intervals.

Proposed savings for the Royal Devon & Exeter Hospital, for which 3,537 of the patients it screens for retinopathy fell into the remit of this study, would be a reduction in costs from 1.83m a year to 1.36m. The study predicts savings of around 25 per cent based on standard assumptions of screening costs.

According to Diabetes UK, some 2.8m people in the UK have diabetes and 10 per cent of them are diagnosed with retinopathy.

The UK's National Institute for Clinical Excellence introduced guidelines for annual screening, but admits that this frequency is arbitrary and has welcomed research to investigate appropriate intervals between screening appointments.

The study was led by Dr. Daniel Chalk, Associate Research Fellow in Applied Operational Research, Peninsula Collaboration for Health, Operational Research and Development (PenCHORD), PCMD. He said: "This is not the first study to investigate screening for diabetic retinopathy, but it is the first to focus on the group of type 2 diabetics who have not yet been diagnosed for the condition. Diabetic retinopathy typically develops at a very slow pace, and as a consequence we wanted to identify whether or not there was any merit in reducing the frequency of screening from annually to every two years."

He added: "We found that there was no perceivable difference in the effectiveness of screening annually or every two years for this particular patient cohort, which would suggest that it would be safe and cost-effective to increase the screening interval to two years. In order to support this, an effective recall system and campaign to impress upon patients the continuing importance of such screening would be beneficial a lengthening of the screening interval in no way undermines the validity of the screening process itself."


'/>"/>

Contact: Andrew Gould
andrew.gould@pcmd.ac.uk
44-188-438-346
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Related medicine news :

1. Study reveals how cancer drug causes diabetic-like state
2. Cardiologists identify mechanism that makes heart disease worse in diabetics
3. Kidney Damage Greatly Raises Diabetics Risk for Death
4. Specific Dietary Goals May Help Diabetics Eat Better
5. Intermittent exercise improves blood glucose control for diabetics
6. Rate of Leg, Foot Amputations Among Diabetics Drops: CDC
7. Short Delay in Treating Blood Pressure Safe for Diabetics: Study
8. KalVista and JDRF form research partnership for novel treatment of diabetic eye disease
9. Poor Sleep May Complicate Young Diabetics Blood Sugar Control
10. Poor sleep linked to increased health and behavior problems in young diabetics
11. Insulin signaling is distorted in pancreases of Type 2 diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: